EVMN
NYSE
$11.53
Evommune Inc (EVMN)
Evommune, Inc. is an innovative biotechnology company focused on developing cutting-edge therapeutics for immunological disorders, targeting significant unmet medical needs in this critical sector. With a promising pipeline and advanced research methodologies, Evommune is positioned to enhance immune response and improve patient outcomes. The company aims to establish a leading presence in the evolving immunotherapy market through its commitment to robust scientific practices and strategic partnerships. As it progresses through clinical trials, Evommune is striving to deliver transformative solutions that could redefine the standards of care in immunology, thereby significantly impacting patient quality of life.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $31.14 (+170.08%)
Market Cap
$448M
Free Cash Flow Yield
-33.76%
Beta (5Y)
0.75
Price Chart
Valuation
Market Cap$448M
P/S44.84
P/B1.42
Profitability
Total Revenue (TTM)$13M
Gross Profit (TTM)$10M
EBITDA-$67M
Operating Margin-900%
EPS-$2.18
Financial Health
Free Cash Flow Yield-33.76%
Growth & Risk
Beta (5Y)0.75
Sharpe Ratio-0.04